Upshear-Smith’s testosterone gel, Vogelxo, was granted final approval by the U.S. Food & Drug Administration (FDA) in June 2014, even as the agency continued to investigate a possible link between serious heart problems and the use of testosterone replacement therapy. Thousands of testosterone lawsuits involving such drugs have been filed in U.S. courts on behalf of men who allegedly suffered heart attacks, strokes and other cardiovascular complications due to their use.
The nationwide law firm of Bernstein Liebhard LLP is now offering free, no-obligation legal reviews to men who may have suffered a heart attack, stroke, deep vein thrombosis, or pulmonary embolism while using prescription low-T therapy. If you or a loved one experienced any of these complications while using Vogelxo, please contact our legal staff at (888) 994-5118 to learn more about filing a Vogelxo lawsuit.
The FDA approved the sale of Vogelxo in May 2014 to treat adult men who have low or no testosterone due to certain underlying medical conditions. The safety and efficacy of this and other prescription low-T drugs in treating men who are experiencing diminished testosterone levels due to aging has not been proven.
Vogelxo is available in 5g tubes and packets in 1- and 30-count packs; it is also available as a 75g metered-dose pump containing 60 metered 1.25 doses. The testosterone gel is applied at the same time each day to the areas of the shoulders and upper arms that will be covered by a short sleeve t-shirt.
The most common Vogelxo side effects include:
Men who already have an enlarged prostate may experience a worsening of symptoms while using Vogelxo. This and other testosterone treatments may also be linked to an increased risk of prostate cancer.
Other serious side effects that may accompany the use of Vogelxo include:
If you or a man you care about suffered a heart attack, stroke or dangerous blood clot while using Vogelxo, now is the time to ensure your legal rights are protected. To learn more about the growing testosterone litigation, please call (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.